A multicenter open-labeled, follow-up trial of levetiracetam in Japanese epilepsy patients with partial onset seizures

Journal of the Japan Epilepsy Society

Volumn 29, Issue 3, 2011, Pages 441-454

  Yagi, Kazuichi ^a   Kameyama, Shigeki ^b   Kaneko, Sunao ^c   Murasaki, Mitsukuni ^d   Yamauchi, Toshio ^e   Yoshida, Katsumi ^f   Suzuki, Atsushi ^f  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b NISHI NIIGATA CHUO NATIONAL HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d Institute of CNS Pharmacology   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f UCB Japan Co Ltd   (Japan)

Author keywords

Add on therapy; Antiepileptic drugs; Epilepsy; Levetiracetam; Long term follow up

Indexed keywords

ETIRACETAM; PLACEBO;

ADD ON THERAPY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEADACHE; HUMAN; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; SOMNOLENCE;

EID: 84858786334     PISSN: 09120890     EISSN: 13475509     Source Type: Journal    
DOI: 10.3805/jjes.29.441     Document Type: Article

References (18)

1. Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, et al. SV2A protein is a broadspectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720.
2. Progress in Medicine 2010; 30: 2903-2910.
3. Brain and Nerve 2011; 63: 247-254.
4. Ben-Menachem E, Falter U, the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg per day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-1283.
5. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I, the United States Levetiracetam Study Group. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242. (Pubitemid 30604624)
6. Shovron SD, Löwenthal A, Janz D, Bielen E, Loiseau P, the European Levetiracetam Study Group. Multicenter double-blind randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-1186.
7. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al., N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66: 1654-1660. (Pubitemid 43964617)
8. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408. (Pubitemid 46208740)
9. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J, N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607-616. (Pubitemid 351294638)
10. Berkovic S, Knowlton R, Leroy R, Schiemann J, Falter U, N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 1751-1760. (Pubitemid 350059304)
11. Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-1774. (Pubitemid 32574586)
12. Depondt C, Yuen AW, Bell GS, Mitchell T, Koepp MJ, Duncan JS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006; 77 (1): 101-103. (Pubitemid 43022705)
13. Kuba R, Novotna I, Brazdil M, Kocvarova J, Tyrlikova I, Mastik J, et al. Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. Acta Neurol Scand 2010; 121: 83-88.
14. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al, for the NEAD Study Group. Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs. N Engl J Med 2009; 360: 1597-1605.
15. Elger CE, Schmidt D. Modern management of epilepsy: A practical approach. Epilepsy & Behav 2008; 12: 501-539.
16. Brodie JM. Medical therapy of epilepsy. When to initiate treatment and when to combine? J Neurol 2005; 252: 125-130.
17. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4: 124-132. (Pubitemid 37184583)